Tenax Therapeutics, formerly Oxygen Biotherapeutics, is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care patients. The Company's main product is levosimendan, which is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand.

TypePublic
HQMorrisville, US
Founded1967
Size (employees)10 (est)
Websitetenaxthera.com
Tenax Therapeutics was founded in 1967 and is headquartered in Morrisville, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Tenax Therapeutics Office Locations

Tenax Therapeutics has an office in Morrisville
Morrisville, US (HQ)
490 1 Copley Pkwy
Show all (1)
Report incorrect company information

Tenax Therapeutics Financials and Metrics

Tenax Therapeutics Revenue

USD

Net income (Q3, 2018)

1.5m

Market capitalization (17-Jan-2019)

3.7m

Closing stock price (17-Jan-2019)

1.2

Cash (30-Sep-2018)

3.3m
Tenax Therapeutics's current market capitalization is $3.7 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

158.9k49.3k

Revenue growth, %

(69%)(100%)

Cost of goods sold

129.8k

Gross profit

29.1k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

55.7k41.9k

Cost of goods sold

3.4k410.0

Gross profit

52.4k41.5k

Gross profit Margin, %

94%99%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

58.3m7.9m10.0m1.6m

Accounts Receivable

36.4k76.5k72.6k50.2k

Current Assets

59.0m17.5m13.6m8.1m

PP&E

124.4k50.3k19.1k9.9k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

2.5m6.3m22.0m3.7m5.1m3.3m1.9m722.2k7.0m2.2m1.8m3.0m3.9m3.3m

Accounts Receivable

64.8k53.1k36.4k98.6k86.3k49.3k24.6k72.6k24.6k24.6k24.6k39.3k39.3k

Inventories

98.0k97.4k

Current Assets

3.1m7.4m26.7m21.6m21.9m16.1m10.2m7.7m12.8m9.0m8.7m7.0m6.7m5.1m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(19.5m)(14.1m)(43.9m)(8.8m)

Depreciation and Amortization

150.5k148.1k19.0k13.6k

Inventories

99.2k

Accounts Payable

(2.1m)2.7m1.9m(5.0m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(5.8m)(9.1m)(2.2m)(3.0m)(6.6m)(5.4m)(10.0m)(14.3m)(3.3m)6.3m(7.5m)(1.2m)(3.1m)(4.6m)

Depreciation and Amortization

74.9k111.2k38.5k12.7k25.0k4.6k9.7k14.5k4.0k7.5k10.6k2.6k5.4k7.6k

Inventories

1.2k1.8k

Accounts Payable

(684.5k)(1.1m)78.6k1.9m830.0k669.5k(987.1k)(3.9m)(5.2m)(684.8k)(331.9k)(339.5k)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Tenax Therapeutics Operating Metrics

FY, 2016

Patents Issued

7

Phase III Trials Products

1

Preclinical Phase Products

1
Show all operating metrics
Report incorrect company information

Tenax Therapeutics Blogs

Tenax Therapeutics to Present at Biotech Showcase Investor Conference

Tenax Therapeutics to Present at Biotech Showcase Investor Conference

Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering

Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering

Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering

Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering

Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial

Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial

Tenax Therapeutics to Present at Upcoming Investor Conferences

Tenax Therapeutics to Present at Upcoming Investor Conferences

Tenax Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference

Tenax Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
Show more

Tenax Therapeutics Company Life and Culture

Report incorrect company information

Tenax Therapeutics Frequently Asked Questions

  • When was Tenax Therapeutics founded?

    Tenax Therapeutics was founded in 1967.

  • How many employees does Tenax Therapeutics have?

    Tenax Therapeutics has 10 employees.

  • Who are Tenax Therapeutics competitors?

    Competitors of Tenax Therapeutics include Cesca Therapeutics, Celldex Therapeutics and Synthetic Biologics.

  • Where is Tenax Therapeutics headquarters?

    Tenax Therapeutics headquarters is located at 490 1 Copley Pkwy, Morrisville.

  • Where are Tenax Therapeutics offices?

    Tenax Therapeutics has an office in Morrisville.

  • How many offices does Tenax Therapeutics have?

    Tenax Therapeutics has 1 office.